Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort

British Journal of Cancer

Volumn 106, Issue 6, 2012, Pages 1095-1099

  Cuzick, J ^a   Berney, D M ^a   Fisher, G ^a   Mesher, D ^a   Moller H ^b   Reid, J E ^c   Perry, M ^c   Park, J ^c   Younus, A ^c   Gutin, A ^c   Foster, C S ^d   Scardino, P ^e   Lanchbury, J S ^c   Stone, S ^c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Myriad Genetic Laboratories   (United States)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

CCP score; cell cycle genes; expression profiles; localised prostate cancer; needle biopsy; prognostic factors

Indexed keywords

PARAFFIN; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER MORTALITY; CANCER STAGING; CELL CYCLE PROGRESSION; CONSERVATIVE TREATMENT; DISEASE SEVERITY; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; RNA EXTRACTION;

ADENOCARCINOMA; AGED; BIOPSY, NEEDLE; CELL CYCLE; COHORT STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TRANSURETHRAL RESECTION OF PROSTATE;

EID: 84862777506     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.39     Document Type: Article

References (17)

1. Billis A (1986) Latent carcinoma and atypical lesions of prostate. An autopsy study. Urology 4: 324-329 (Pubitemid 17062539)
2. Brawley OW (1997) Prostate carcinoma incidence and patient mortality: the effects of screening and early detection. Cancer 80(9): 1857-1863 (Pubitemid 27475949)
3. Breslow N, Chan CW, Dhom G, Drury RA, Franks LM, Gellei B, Lee YS, Lundberg S, Sparke B, Sternby NH, Tulinius H (1977) Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer 20(5): 680-688
4. Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, Gleitsmann K, Koenig HC, Lam C, Maltz A, Rugge JB, Lin K (2011) Screening for prostate cancer: a review of the evidence for the US Preventive services task force. Ann Intern Med 155(11): 762-771
5. Cuzick J, Fisher G, Kattan MW, Berney D, Oliver T, Foster CS, Møller H, Reuter V, Fearn P, Eastham J, Scardino P, Transatlantic Prostate Group (2006) Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer 95: 1186-1194 (Pubitemid 44658482)
6. Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, Mesher D, Speights VO, Stankiewicz E, Foster CS, Møller H, Scardino P, Warren JD, Park J, Younus A, Flake II DD, Wagner S, Gutin A, Lanchbury JS, Stone S, Transatlantic Prostate Group (2011) Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 12(3): 245-255
7. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ (2002) Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends. J Natl Cancer Inst 94(13): 981-990 (Pubitemid 34814727)
8. Fentiman IS, Cuzick J, Millis RR, Hayward JL (1984) Which patients are cured of breast cancer? BMJ 289: 1108-1111 (Pubitemid 15201223)
9. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12): 2893-2917
10. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer Statistics 2009. CA Cancer J Clin 59: 225-249
11. Jhavar S, Corbishley CM, Dearnaley D, Fisher C, Falconer A, Parker C, Eeles R, Cooper CS (2005) Construction of tissue microarrays from prostate needle biopsy specimens. Br J Cancer 93(4): 478-482 (Pubitemid 43080024)
12. Lu-Yao GL, Greenberg ER (1994) Changes in prostate cancer incidence and treatment in USA. Lancet 343(8892): 251-254 (Pubitemid 24039623)
13. Montironi R, Mazzuccheli R, Scarpelli M, Lopez-Beltran A, Fellegara G, Algaba F (2005) Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: contemporary approach, current clinical significance and sources of pathology discrepancies. BJU Int 95(8): 1146-1152 (Pubitemid 40799472)
14. Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ, Haas GP (1994) High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between ages of 20-69: autopsy study of 249 cases. In Vivo 8: 439-443
15. Sánchez-Chapado M, Olmedilla G, Cabeza M, Donat E, Ruiz A (2003) Prevalence of prostate cancer and prostatic intraepithelial neoplasia in Caucasian Mediterranean males: an autopsy study. Prostate 54(3): 238-247 (Pubitemid 36120322)
16. Soos G, Tsakiris I, Szanto J, Turzo C, Haas PG, Dezso B (2005) The prevalence of prostate carcinoma and its precursor in Hungary: an autopsy study. Eur Urol 48(5): 739-744 (Pubitemid 41495371)
17. WHO (2010) International statistical classification of diseases and related health problems, 10th revision, 4th edn, ISBN 978 92 4 1548342 http://www.who.int/classifications/icd/ICD10Volume2-en-2010.pdf